Curatively Intended Thoracic Reirradiation

Launched by UNIVERSITY OF AARHUS · Apr 22, 2025

Keywords

ClinConnect Summary

The CURE Lung trial is a research study focused on patients with thoracic cancers, including lung cancer, who may need to undergo a second round of radiation treatment (called reirradiation). This trial aims to gather important information about the side effects caused by radiation, how well the treatment works in controlling the cancer, and overall survival rates for these patients. By collecting this data, the researchers hope to develop safer ways to deliver reirradiation, ultimately helping more patients benefit from it without facing severe side effects.

To participate in the trial, individuals must be at least 18 years old and have previously received radiation therapy for their thoracic cancer. They should also have a good enough lung function to tolerate another course of treatment and must be expected to live at least six more months. Potential participants will need to provide consent and may undergo various assessments to ensure they fit the criteria. This study is not yet recruiting participants, but once it begins, it will help shape better treatment strategies for long-term survivors of lung cancer and related conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.
• • Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
• • Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
• • Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
• • Adequate lung function to tolerate treatment, at the discretion of the treating physician.
• • Ability to complete a radiotherapy course with the aim of local control.
• • ECOG Performance status 0-2.
• • Estimated life expectancy ≥ 6 months
• • Age ≥18 years
• • Signed informed consent
• Exclusion Criteria:
• • Uncontrolled other malignancy.
• • The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
• • Pregnancy
• • Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.